Sonoma Pharmaceuticals Reports Director/Officer Changes & Financials
Ticker: SNOA · Form: 8-K · Filed: Oct 9, 2025 · CIK: 1367083
Sentiment: neutral
Topics: management-change, compensation, financials
Related Tickers: SNOA
TL;DR
Sonoma Pharma (SNOA) filed an 8-K: board/officer changes, comp details, and financials. Event date Oct 3, 2025.
AI Summary
Sonoma Pharmaceuticals, Inc. filed an 8-K on October 9, 2025, reporting changes in its board of directors and officers, along with updates to compensatory arrangements. The filing also includes financial statements and exhibits, with the earliest event reported on October 3, 2025. The company, formerly known as Oculus Innovative Sciences, Inc., is incorporated in Delaware and headquartered in Boulder, Colorado.
Why It Matters
Changes in a company's leadership and executive compensation can signal shifts in strategy or operational focus, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in directors and officers, coupled with compensatory arrangements, can indicate internal shifts that may carry operational or strategic risks.
Key Players & Entities
- Sonoma Pharmaceuticals, Inc. (company) — Registrant
- Oculus Innovative Sciences, Inc. (company) — Former company name
- October 3, 2025 (date) — Earliest event reported
- October 9, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- Boulder, CO (location) — Business address
FAQ
What specific items are being reported in this 8-K filing?
This 8-K filing reports on the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements of certain officers. It also includes financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on October 3, 2025.
What is the exact name of the registrant?
The exact name of the registrant is Sonoma Pharmaceuticals, Inc.
What was Sonoma Pharmaceuticals, Inc. formerly known as?
Sonoma Pharmaceuticals, Inc. was formerly known as Oculus Innovative Sciences, Inc.
Where is Sonoma Pharmaceuticals, Inc. incorporated and what is its business address?
Sonoma Pharmaceuticals, Inc. is incorporated in Delaware and its business address is 5445 Conestoga Court, Suite 150, Boulder, CO 80301.
Filing Stats: 1,083 words · 4 min read · ~4 pages · Grade level 11.5 · Accepted 2025-10-09 16:30:56
Key Financial Figures
- $475,000 — eed to pay Ms. Trombly a base salary of $475,000 per annum. Ms. Trombly will be eligible
- $300,000 — we will pay him severance consisting of $300,000, contingent upon his execution of a gen
Filing Documents
- sonoma_8k.htm (8-K) — 33KB
- sonoma_ex1001.htm (EX-10.1) — 154KB
- 0001683168-25-007478.txt ( ) — 387KB
- snoa-20251003.xsd (EX-101.SCH) — 3KB
- snoa-20251003_lab.xml (EX-101.LAB) — 33KB
- snoa-20251003_pre.xml (EX-101.PRE) — 22KB
- sonoma_8k_htm.xml (XML) — 4KB
02
Item 5.02. Departure of Directors of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Amended and Restated Employment Agreement with our Chief Executive Officer Effective October 3, 2025, we entered into an amended and restated employment agreement with our Chief Executive Officer, Amy Trombly. Under the amended and restated agreement, we agreed to pay Ms. Trombly a base salary of $475,000 per annum. Ms. Trombly will be eligible to receive a target annual bonus of 50% of her base salary, which shall be in the discretion of the Compensation Committee. Consistent with best practices, the definition of Cause was expanded to include material failure by Ms. Trombly to comply with the Company's written policies or rules, if such failure is reasonably likely to cause material, reputational or financial harm to the Company. Also consistent with best practices, the definition of Good Reason excludes base salary reductions up to 10% as applied consistently to similarly-situated executives. Good Reason also excludes the failure by a successor to the Company to assume the terms of the amended and restated agreement. In the event of termination without Cause or for Good Reason, Ms. Trombly's severance payment is to be paid in accordance with regular payroll rather than as a lump sum payment, consistent with best practices, and COBRA reimbursement is extended to up to twelve months following termination for Ms. Trombly, her spouse or domestic partner and her dependents. In the event of termination without Cause or for Good Reason in connection with a Change in Control, Ms. Trombly's severance payment is increased to two times her annual base salary and two times her target annual bonus, and COBRA reimbursement is extended to up to twenty-four months following termination for Ms. Trombly, her spouse or domestic partner and her dependents. In the event of termination due to death or disability, COBRA rei
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 10.1 Amended and Restated Employment Agreement by and between the Company and Amy Trombly, dated October 3, 2025. 104 Cover Page Interactive Data File (formatted in Inline XBRL in Exhibit 101).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SONOMA PHARMACEUTICALS, INC. Date: October 9, 2025 By: /s/ Amy Trombly Name: Title: Amy Trombly Chief Executive Officer 3